Royalty Pharma plc Files Proxy Statement for Proposed Transaction

TL;DR

Royalty Pharma is gearing up for a big deal, starting the shareholder approval process.

AI Summary

Royalty Pharma plc is filing a DEFA14A, indicating it is soliciting materials prior to furnishing a definitive proxy statement for a proposed transaction. The filing, dated January 16, 2025, concerns preliminary communications with security holders regarding this upcoming transaction. The company is based in New York, NY.

Why It Matters

This filing signals that Royalty Pharma is moving forward with a significant corporate transaction and is beginning the formal process of seeking shareholder approval.

Risk Assessment

Risk Level: low — This is a standard procedural filing for a proposed transaction, not an indication of immediate financial risk.

Key Players & Entities

• Royalty Pharma plc (company) — Registrant and subject of the filing
• 110 EAST 59TH STREET (location) — Business and mailing address of Royalty Pharma plc
• NEW YORK (location) — City of Royalty Pharma plc's address
• 10022 (location) — ZIP code of Royalty Pharma plc's address

FAQ

Key Financial Figures

• $2.8 b — eceipts, our top line, of approximately $2.8 billion, which is at the high end of our
• $1.2 billion — have the combined potential to deliver $1.2 billion annually in new Royalty Receipts to Roy
• $2.8 billion — ions, and we deployed capital of around $2.8 billion to further broaden our portfolio. We're
• $3 billion — n strategy and recently announced a new $3 billion share repurchase plan given the discoun
• $1.1 billion — a total consideration of approximately $1.1 billion. Of this, around $100 million will be i
• $100 million — oximately $1.1 billion. Of this, around $100 million will be in upfront cash. On top of this
• $380 million — On top of this, the company will assume $380 million of existing Manager debt, importantly,
• $1.6 billion — ings are expected to reach greater than $1.6 billion. Slide 7 highlights the multiple benef
• $175 million — on in 2026, which will increase to over $175 million in 2030. Cumulatively, the savings will
• $2.8 billion — views, for an announced value of around $2.8 billion. Slide 9 shows the performance of our
• $25 billion — y, we have deployed capital of close to $25 billion since 2012, with a healthy balance betw
• $925 million — r for synthetic royalty transactions of $925 million in 2024. This represents a more than do
• $15.5 billion — rs. You can see here that approximately $15.5 billion of transactions we have announced since
• $6 b — ns we have announced since 2020, around $6 billion, or nearly 40%, has been with rep
• $2 billion — Our current intention is to repurchase $2 billion of our shares in 2025, although the tot

Filing Documents

• dp223541_defa14a.htm (DEFA14A) — 65KB
• 0000950103-25-000590.txt ( ) — 66KB

From the Filing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) (2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material Pursuant to Section 240.14a-12 Royalty Pharma plc (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement if other than the Registrant) Payment of Filing Fee (Check the appropriate box): No fee required. Fee paid previously with preliminary materials Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 This Schedule 14A relates solely to preliminary communications made prior to furnishing security holders of Royalty Pharma plc (the "Company") with a definitive proxy statement related to a proposed transaction in which the Company's subsidiary, Royalty Pharma Holdings Ltd. ("RPH"), entered into a Membership Interest Purchase Agreement with Royalty Pharma, LLC ("RP LLC"), a Delaware limited liability company, RP Management, LLC, a Delaware limited liability company, and the sellers named therein (the "Sellers"), pursuant to which, upon the terms and subject to the conditions set forth therein, RPH will acquire all of the equity interests of RP LLC from the Sellers. This Schedule 14A consists of excepts from a transcript of a conference held on January 14, 2025 involving Pablo Legorreta, Terrance Coyne, Marshall Urist and Christopher Hite of Royalty Pharma plc, on the one hand, and JPMorgan, on the other hand. *** Event ID: 140559071257 Event Name: Royalty Pharma PLC at JPMorgan Healthcare Conference Event Date: 2025-01-14T23:45:00 UTC C: Pablo Legorreta;Royalty Pharma PLC;Founder, Chief Executive Officer C: Terrance Coyne;Royalty Pharma PLC; Executive Vice President - Chief Financial Officer C: Marshall Urist;Royalty Pharma PLC;Executive Vice President - Research and Investments C: Christopher Hite;Royalty Pharma PLC;Executive Vice President – Vice Chairman P: Chris Schott;JPMorgan;Analyst +++ presentation Chris Schott^ Good afternoon, everybody. I'm Chris Schott from JPMorgan, and it's my pleasure to be introducing Royalty Pharma today. We thought this is a very interesting business model, a really unique way that Royalty is helping finance some of the innovation occurring across the biopharma business. So looking forward to our presentation from the company's Founder and CEO, Pablo Legorreta. We're going to have Pablo do your presentation, and then we'll open up to our Q&A from there. So with that, Pablo, Happy New Year. Thank you for your presentation. Pablo Legorreta^ Thank you very much. Good afternoon, and good morning for some other people that are following us in other places around the world. My name is Pablo Legorreta, and I'm the Founder and CEO of Royalty Pharma. I'm thrilled to be here to share my excitement for our business. What I plan to leave you with today are two important takeaways: first, the fundamentals of a business that has never been stronger; and second, we're taking major steps to enhance shareholder value, which we announced on Friday. Before I begin, you can see on this slide our customary forward-looking statements. Moving to slide 4. We're very proud of our achievements in 2024. We again delivered strong financial performance and significantly enhanced our portfolio through strong capital deployment. As announced in our press release on Friday, we expect to deliver Portfolio Receipts, our top line, of approximately $2.8 billion, which is at the high end of our previous guidance range. In underlying terms, this represents Royalty Receipts growth of around 13% and continues our track record of strong growth since our IPO. In terms of our portfolio, we added royalties on eight new therapies, including four development-stage therapies. We saw positive news across our portfolio, including FDA approvals of Voranigo for brain cancer, Cobenfy for schizophrenia, and Tremfya for ulcerative colitis. Looking ahead, we are really excited about our development pipeline of potential royalties on over 40 projects. Based on market forecasts, the potential therapies in our late-stage pipeline have the combined potential to deliver $1.2 billion annually in new Royalty Receipts to Royalty Pharma. In terms of capital allocation, we had another very attractive year for royalty transactions, and we deployed capital of around $2.8 billion to further broaden our portfolio. We're also evolving our capital allocation strategy and recently announced a new $3 billion share repurchase plan given the discount to intrinsic value at which our shares are trading. The scale of this commitment is substantial, representing aro

View Full Filing

View this DEFA14A filing on SEC EDGAR